Eli Lilly (LLY)
1,188.58
-28.37 (-2.33%)
NYSE· Last Trade: Jul 11th, 4:59 PM EDT
Detailed Quote
| Previous Close | 1,216.95 |
|---|---|
| Open | 1,210.31 |
| Bid | 1,188.14 |
| Ask | 1,189.00 |
| Day's Range | 1,178.32 - 1,212.96 |
| 52 Week Range | 623.78 - 1,249.45 |
| Volume | 2,010,191 |
| Market Cap | 1.14T |
| PE Ratio (TTM) | 51.79 |
| EPS (TTM) | 22.9 |
| Dividend & Yield | 6.920 (0.58%) |
| 1 Month Average Volume | 3,110,024 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.
Via The Motley Fool · July 11, 2026
BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.
Via The Motley Fool · July 11, 2026
One small investment offers big benefits for Nvidia.
Via The Motley Fool · July 11, 2026
This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.
Via The Motley Fool · July 11, 2026
There are good reasons to invest in Lilly and to hold off.
Via The Motley Fool · July 11, 2026
It's something very simple.
Via The Motley Fool · July 11, 2026
So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.
Via The Motley Fool · July 10, 2026
Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.
Via The Motley Fool · July 10, 2026
Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.
Via The Motley Fool · July 9, 2026
PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost.
Via The Motley Fool · July 9, 2026
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
Via The Motley Fool · July 9, 2026
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Via StockStory · July 9, 2026
Investing for the long-term requires a different strategy.
Via The Motley Fool · July 8, 2026
PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost.
Via The Motley Fool · July 8, 2026
The stock has soared 400% in recent years.
Via The Motley Fool · July 8, 2026
As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.
Via MarketBeat · July 8, 2026
Check out the companies making headlines yesterday: Carlisle (NYSE:CSL): Building envelope solutions provider Carlisle Companies (NYSE:CSL) fell by 4.2% on T...
Via StockStory · July 8, 2026
Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.
Via The Motley Fool · July 8, 2026
Wall Street is getting more bullish on the pharma giant's shares.
Via The Motley Fool · July 7, 2026
Don't sleep on these medical device leaders.
Via The Motley Fool · July 7, 2026
The stock is down, but it isn't out yet.
Via The Motley Fool · July 7, 2026
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his pri...
Via StockStory · July 7, 2026
Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.
Via The Motley Fool · July 7, 2026
This key factor didn't exist when Buffett first gave the advice, but does that change its appeal?
Via The Motley Fool · July 7, 2026
Eli Lilly shares hit a new record high Tuesday after IPO stock Kailera posted lackluster test results for its obesity drug.
Via Investor's Business Daily · July 7, 2026